Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 10/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 2/20 | 1.00 |
| ▸ | PGR | P06401 | 1/20 | 1.00 |
| ▸ | CES2 | O00748 | 1/20 | 0.68 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.68 |
| ▸ | LMNA | P02545 | 1/20 | 0.68 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.68 |
| ▸ | GLA | P06280 | 1/20 | 0.68 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.68 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.68 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.68 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.68 |
| ▸ | TSHR | P16473 | 1/20 | 0.68 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.68 |
| ▸ | AADAC | P22760 | 1/20 | 0.68 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.68 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.68 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.68 |
| ▸ | HTT | P42858 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydroxyflutamide SCHEMBL29379312 | 1.00 | AR (1.00) | ARCYP3A4PGRCES2ABCB11 | |
| Hydroxyflutamide SCHEMBL10395764 | 0.96 | AR (0.93) | ARCYP3A4PGRCES2ABCB11 | |
| Hydroxyflutamide SCHEMBL10395767 | 0.96 | AR (0.93) | ARCYP3A4PGRCES2ABCB11 | |
| SCHEMBL11407111 | 0.92 | AR (0.85) | ARCYP3A4PGRCES2ABCB11 | |
| SCHEMBL14086876 | 0.91 | AR (0.83) | ARCYP3A4PGRCES2ABCB11 | |
| SCHEMBL2011994 | 0.90 | AR (0.82) | ARCYP3A4PGRCES2ABCB11 | |
| SCHEMBL7524151 | 0.90 | AR (0.81) | ARCYP3A4PGRCES2ABCB11 | |
| SCHEMBL14086877 | 0.90 | AR (0.81) | ARCYP3A4PGRCES2ABCB11 | |
| SCHEMBL8409001 | 0.89 | AR (0.81) | ARCYP3A4PGRCES2ABCB11 | |
| SCHEMBL8410375 | 0.88 | AR (0.79) | ARCYP3A4PGRCES2ABCB11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 78 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1738752-A1 | Pharmaceutical combinations comprising cis-retine acid | Schering Aktiengesellschaft (DE) | 2007-01-03 | — | — | EP | claimed |
| EP-1641458-A2 | PHARMACEUTICAL COMBINATIONS OF PHTHALAZINE VEGF INHIBITORS AND BENZAMIDE HDAC INHIBITORS | SCHERING AKTIENGESELLSCHAFT (DE) | 2006-04-05 | — | — | EP | claimed |
| US-20050054647-A1 | New pharmaceutical combination | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2005-03-10 | — | — | US | claimed |
| WO-2004058234-A2 | PHARMACEUTICAL COMBINATIONS OF PHTHALAZINE VEGF INHIBITORS AND BENZAMIDE HDAC INHIBITORS | SCHERING AKTIENGESELLSCHAFT (DE) | 2004-07-15 | — | — | WO | claimed |
| US-4598072-A | Combinations of an aromatase-inhibitor and an antiandrogen for prophylaxis and/or treatment of benign prostatic hyperplasia | SCHERING AKTIENGESELLSCHAFT (DE) | 1986-07-01 | — | — | US | claimed |
| US-4039684-A | 4-NITRO-3-TRIFLUOROMETHYL-ISOBUTYRANILIDE OR CORRESPONDING 2-HYDROXY- COMPOUND | SCHERING CORPORATION (US) | 1977-08-02 | — | — | US | claimed |
| WO-2024010817-A2 | SELECTIVE ANDROGEN RECEPTOR DEGRADER (SARD) O-LINKED LIGANDS AND METHODS OF USE THEREOF | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2024-01-11 | — | — | WO | disclosed |
| US-20230382870-A1 | N-AROMATIC AMIDE COMPOUNDS, PREPARATION METHODS AND USES THEREOF | SHENZHEN EDK PHARMACEUTICAL TECH CO LTD (CN) | 2023-11-30 | — | — | US | disclosed |
| EP-3357513-B1 | PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF | KANGPU BIOPHARMACEUTICALS LTD (CN) | 2023-10-25 | — | — | EP | disclosed |
| EP-3357513-B1 | PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF | KANGPU BIOPHARMACEUTICALS LTD (CN) | 2023-10-25 | — | — | EP | disclosed |
| US-11760727-B2 | N-aromatic amide compounds, preparation methods and uses thereof | SHENZHEN EDK PHARMACEUTICAL TECHNOLOGY CO., LTD. (CN) | 2023-09-19 | — | — | US | disclosed |
| US-20230227492-A1 | MONOMERIC AND OLIGOMERIC COMPOUND EMBODIMENTS AS CONTRACEPTIVES AND THERAPIES AND METHODS OF MAKING AND USING THE SAME | THE USA AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2023-07-20 | — | — | US | disclosed |
| EP-4164743-A2 | MONOMERIC AND OLIGOMERIC COMPOUND EMBODIMENTS AS CONTRACEPTIVES AND THERAPIES AND METHODS OF MAKING AND USING THE SAME | The United States of America, as represented by The Secretary, Department of Health and Human Services (US) | 2023-04-19 | — | — | EP | disclosed |
| WO-1992016233-A1 | PHARMACEUTICAL COMBINATION FOR THE TREATMENT OF PROSTATIC CANCER CONTAINING A 5 ALPHA REDUCTASE INHIBITOR AND AN ANTIANDROGEN | MERCK & CO., INC. (US) | 1992-10-01 | — | — | WO | disclosed |
| US-4921941-A | TRIPEPTIDE ESTERS | SCHERING CORPORATION (US) | 1990-05-01 | — | — | US | disclosed |
| EP-0348564-A1 | Orally active antiandrogens | SCHERING CORPORATION (US) | 1990-01-03 | — | — | EP | disclosed |
| WO-1989000165-A1 | ORALLY ACTIVE ANTIANDROGENS | SCHERING CORPORATION (US) | 1989-01-12 | — | — | WO | disclosed |
| US-4598072-A | Combinations of an aromatase-inhibitor and an antiandrogen for prophylaxis and/or treatment of benign prostatic hyperplasia | SCHERING AKTIENGESELLSCHAFT (DE) | 1986-07-01 | — | — | US | disclosed |
| US-4039684-A | 4-NITRO-3-TRIFLUOROMETHYL-ISOBUTYRANILIDE OR CORRESPONDING 2-HYDROXY- COMPOUND | SCHERING CORPORATION (US) | 1977-08-02 | — | — | US | disclosed |
| US-4039684-A | 4-NITRO-3-TRIFLUOROMETHYL-ISOBUTYRANILIDE OR CORRESPONDING 2-HYDROXY- COMPOUND | SCHERING CORPORATION (US) | 1977-08-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230227492-A1 | MONOMERIC AND OLIGOMERIC COMPOUND EMBODIMENTS AS CONTRACEPTIVES AND THERAPIES AND METHODS OF MAKING AND USING THE SAME | SHBG, CYP19A1, GNRHR | AR 7/4885CYP3A4 2085/4885PGR 16/4885 |
| US-20050054647-A1 | New pharmaceutical combination | VEGFA, INHA, PGF | AR 300/4885CYP3A4 1151/4885PGR 116/4885 |
| US-20230382870-A1 | N-AROMATIC AMIDE COMPOUNDS, PREPARATION METHODS AND USES THEREOF | H1-3, H1-0, NAT1 | AR 385/4885CYP3A4 687/4885PGR 1068/4885 |
| US-11760727-B2 | N-aromatic amide compounds, preparation methods and uses thereof | AR, BPHL, CYP19A1 | AR 1/4885CYP3A4 239/4885PGR 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.